March 1, 2017
(Reuters) – Juno Therapeutics Inc on Wednesday said it decided to shut down development of an experimental leukemia treatment from a highly promising new class of immunotherapy following an investigation into toxicity that led to a handful of patient deaths. The drug, JCAR015, uses a technology known as CAR-T being pursued by other companies as well. CAR-T therapy removes a key component of the immune system called T cells from a patient’s blood and re-engineers them to more efficiently attack cancer before returning them to the patient.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.